Early Drug Development / Phase One Clinical Trials

The Early Drug Development (EDD) team offers clinical trials that test new treatments sometimes for the first time in humans. The purpose of these clinical trials are to find a safe dose of the treatment and to determine if it is working against cancer. These trials may be open to one or multiple different cancer types.

If you would like to be considered for a clinical trial you will require a referral from your current treating team. Visit the Joining a Clinical Trial page for referral information. 

For more information on clinical trials, get in contact with our cancer clinical trials enquiry coordinator.

Clinical Trials Enquiry Coordinator

Business hours, Mon to Friday between 9am - 2pm
Email [email protected]
Phone (03) 8559 7456

Open and Recruiting Clinical Trials

A clinical trial to test the safety and effectiveness of two treatments BGB-283 and PD-0325901 given together in patients that have solid cancers with genetic changes that cause the cancer to grow

Cancer type

Selected solid cancer types (cancer in the ‘solid’ organs such as breast or lung) with changes in the genes of the cancer

Status

Open and recruiting

Phase

One/two: A phase one / two clinical trial combines a phase one and two. The phase one tests new treatments sometimes for the first time in humans, usually in a small group of patients. The phase two part tests the new treatment in a larger group of patients with selected cancer types. The aim of a phase one / two is to find the best dose of the new treatment and see if it works against the cancer.

Brief summary

A clinical trial to find the best dose of a combined treatment (BGB-283 and PD-0325901) given to patients with certain solid cancers (cancer in the ‘solid’ organs such as breast or lung) with genetic changes that cause the cancer to grow. The clinical trial will test if the combined treatment can shrink the cancer or stop the cancer from growing.

Who can participate

Patients who:

  • Have a solid cancer with genetic changes that cause the cancer to grow
  • Have cancer that has spread to other parts of the body
  • Have had treatment for their cancer but it has become worse or has not responded to treatment

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

A clinical trial to test the safety and effectiveness of a new oral treatment (GSK3368715) in patients with solid cancer types and non-Hodgkin’s lymphoma

Cancer type

Solid cancers (cancer in the ‘solid’ organs such as breast or lung) or Diffuse Large B-Cell Lymphoma

Status

Open and recruiting

Phase

One: A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one is to test the safety of the new treatment and find the best dose to give patients.

Brief summary

A clinical trial to find the best dose of an oral treatment (GSK3368715) alone and in combination with other treatments in patients with solid cancers (cancer in the ‘solid’ organs such as breast or lung) or Diffuse Large B-Cell Lymphoma. The clinical trial will test if the treatment can shrink the cancer or stop the cancer from growing.

Who can participate

Patients who:

  • Have cancer that has spread to other parts of the body

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

A clinical trial to test the safety and effectiveness of a new treatment BGB-A425, given together with an immunotherapy treatment, Tislelizumab, in patients with advanced solid cancers

Cancer type

All Solid cancers (cancer in the ‘solid’ organs such as breast or lung)

Status

Open and recruiting

Phase

One/two: A phase one / two clinical trial combines a phase one and two. The phase one tests new treatments sometimes for the first time in humans, usually in a small group of patients. The phase two part tests the new treatment in a larger group of patients with selected cancer types. The aim of a phase one / two is to find the best dose of the new treatment and see if it works against the cancer.

Brief summary

A clinical trial to find the best dose of a combined treatment (BGB-A425 and Tislelizumab) given to patients with solid cancers (cancer in the ‘solid’ organs such as breast or lung).  The clinical trial will test if the combined treatment can shrink the cancer or stop the cancer from growing.

Who can participate

Patients who:

  • Have cancer that has spread to other parts of the body

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

A clinical trial to test the safety and effectiveness of a new treatment NZV930 in combination with PDR001 and/or NIR178 in patients with selected advanced solid cancers

Cancer type

Non-Small Cell Lung Cancer, Triple Negative Breast Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer Microsatellite Stable, Ovarian Cancer and Renal Cell Carcinoma

Status

Open and recruiting

Phase

One/two: A phase one / two clinical trial combines a phase one and two. The phase one tests new treatments sometimes for the first time in humans, usually in a small group of patients. The phase two part tests the new treatment in a larger group of patients with selected cancer types. The aim of a phase one / two is to find the best dose of the new treatment and see if it works against the cancer.

Brief summary

A clinical trial to find the best dose of the new treatments (treatment NZV930 in combination with PDR001 and/or NIR178) given to patients with selected solid cancers (cancer in the ‘solid’ organs such as breast or lung). The clinical trial will test if the combined treatment can shrink the cancer or stop the cancer from growing.

Who can participate

Patients who:

  • Have a solid cancer that is recruiting in this study
  • Have cancer that has spread to other parts of the body

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

A clinical trial to test the safety and effectiveness of a new treatment (BFCR4350A) for patients with Multiple Myeloma

Cancer type

Multiple Myeloma 

Status

Open and recruiting

Phase

One: A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one is to test the safety of the new treatment and find the best dose to give patients.

Brief summary

A clinical trial to find the best dose of a new treatment (BFCR4350A) in patients with multiple myeloma. The clinical trial will test if the treatment can shrink the cancer or stop the cancer from growing.

Who can participate

Patients who:

  • Have Multiple Myeloma
  • Have had treatment for their cancer but it has become worse or has not responded to treatment

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

A clinical trial to test the safety and effectiveness of (RO7296682) for the treatment of advanced solid cancers

Cancer type

All solid cancer types (cancer in the ‘solid’ organs such as breast or lung)

Status

Open and recruiting

Phase

One: A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one is to test the safety of the new treatment and find the best dose to give patients.

Brief summary

A clinical trial to find the best dose of a new treatment (RO7296682) given to patients with advanced solid cancer types (cancer in the ‘solid’ organs such as breast or lung). The clinical trial will test if the treatment can shrink the cancer or stop the cancer from growing.

Who can participate

Patients who:

  • Have a solid cancer that has spread to other parts of the body
  • Have had treatment for their cancer but it has become worse or has not responded to treatment

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

A clinical trial to test the safety and effectiveness of TetMYB vaccine and an immunotherapy treatment for the treatment of patients with Colorectal or Adenoid Cystic Carcinoma

Cancer type

Colorectal or Adenoid Cystic Carcinoma

Status

Open and recruiting

Phase

One: A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one is to test the safety of the new treatment and find the best dose to give patients.

Brief summary

A clinical trial to find the best dose of a new vaccine with an immunotherapy treatment in patients with Colorectal or Adenoid Cystic Carcinoma. The clinical trial will test if the combined treatment can shrink the cancer or stop the cancer from growing.

Who can participate

Patients who:

  • Have Colorectal cancer or Adenoid Cystic Carcinoma
  • Have cancer that has spread to other parts of the body

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

A clinical trial to test the safety and effectiveness of a new treatment MEDI5752 for the treatment of patients with advanced solid cancers

Cancer type

Advanced solid cancers (cancer in the ‘solid’ organs such as breast or lung)

Status

Open and recruiting

Phase

One: A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one is to test the safety of the new treatment and find the best dose to give patients.

Brief summary

A clinical trial to find the best dose of a new treatment (MEDI5752) in patients with advanced solid cancer types (cancer in the ‘solid’ organs such as breast or lung) who have progressed or not responded to prior treatment. The clinical trial will test if the treatment can shrink the cancer or stop the cancer from growing.

Who can participate

Patients who have:

  • Have cancer that has spread to other parts of the body

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

A clinical trial to test the safety and effectiveness of a new treatment AMG 701 in patients with Multiple Myeloma

Cancer type

Multiple Myeloma (some types may be excluded)

Status

Open and recruiting

Phase

One:  A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one is to test the safety of the new treatment and find the best dose to give patients.

Brief summary

A clinical trial to find the best dose of a new treatment in patients with Multiple Myeloma who have progressed or not responded to prior treatment. The clinical trial will test if the treatment can shrink the cancer or stop the cancer from growing.

Who can participate

Patients who:

  • Have Multiple Myeloma
  • Have had treatment for their cancer but it has gotten worse or have not responded to treatment given for their cancer

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

A clinical trial to test the safety and effectiveness of a new treatment AMG 510 in patients with advanced solid cancers with a genetic change (KRAS G12C mutation) that causes the cancer to grow

Cancer type

Advanced solid cancers (cancer in the ‘solid’ organs such as breast or lung) with KRAS G12C mutation 

Status

Open and recruiting

Phase

One: A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one is to test the safety of the new treatment and find the best dose to give patients.

Brief summary

A clinical trial to find the best dose of a new treatment in patients with advanced solid cancer types (cancer in the ‘solid’ organs such as breast or lung) with a KRAS G12C mutation who have progressed or not responded to previous treatment. This treatment targets the KRAS G12C gene, which is present in a small number of solid cancers. The clinical trial will test if the treatment can shrink the cancer or stop the cancer from growing.

Who can participate

Patients who:

  • Have a solid cancer with a KRAS G12C mutation 
  • Have cancer that has spread to other parts of the body
  • Have had treatment for their cancer but it has gotten worse or have not responded to treatment given for their cancer
  • Are able to swallow medication by mouth

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

A clinical trial investigating Pembrolizumab for the treatment of selected advanced solid cancers

Cancer type

Selected advanced solid cancers (cancer in the ‘solid’ organs such as breast or lung)

Status

Open and recruiting

Phase

Two: A phase two clinical trial follows a phase one, in a large group of patients with selected cancer types. The aim of a phase two is to find out if the new treatment is effective in these cancer types.

Brief summary

This clinical trial is assessing the safety and recommended dose of Pembrolizumab for treatment of selected advanced solid cancer types (cancer in the ‘solid’ organs such as breast or lung). The clinical trial will test if the treatment can shrink the cancer or stop the cancer from growing.

Who can participate

Patients who have:

  • Have a solid cancer that is recruiting in this study
  • Have cancer that has spread to other parts of the body
  • Have not responded to treatment given for their cancer type

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

A clinical trial to test the safety and effectiveness of a new treatment BGB-A445, given alone or together with an immunotherapy treatment, Tislelizumab, in patients with advanced solid cancers

Cancer type

Advanced solid cancers (cancer in the ‘solid’ organs such as breast or lung)

Status

Open and recruiting

Phase

One: A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one is to test the safety of the new treatment and find the best dose to give patients.

Brief summary

A clinical trial to find the best dose of a new treatment BGB-A445 alone or together with Tislelizumab in patients with advanced solid cancer types (cancer in the ‘solid’ organs such as breast or lung).The clinical trial will test if the combined treatment can shrink the cancer or stop the cancer from growing.

Who can participate

Patients who have:

  • Have cancer that has spread to other parts of the body
  • Have had treatment for their cancer but it has gotten worse or have not responded to treatment given for their cancer

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.